What Is Behind The Move In Insmed Stock?

INSMYTD-17.0%SPYYTD+5.8%XLVYTD+16.1%
Analyze INSM →

Today’s big story: Will 2027 Be A 2022 Repeat For Stocks?

Insmed (INSM) stock rose 20.6% on Thursday, November 19, 2026, while the S&P 500 fell 2.0%. The jump came after reports that day that Sanofi is considering an acquisition of Insmed. There was no earnings report or SEC filing from the company itself. Talk of a buyer puts a spotlight on what Insmed actually sells. So how big has the business behind the takeover talk become?

Image from Pixabay

How Big Has Insmed’s Business Become?

Insmed reported revenue of $524 million in the third quarter of 2026, up 268.4% from a year earlier. Its main drug is BRINSUPRI, a treatment for bronchiectasis. Management said on the October 29 call that BRINSUPRI brought in $400.1 million that quarter, up 29% from the quarter before.

On the same call, the company raised its full-year 2026 sales forecast for BRINSUPRI to $1.35 billion to $1.4 billion. That is a forecast, not a result, but it is higher than the one it replaced.

The business still runs at a loss, though a smaller one. Insmed recorded an $81.8 million operating loss in the third quarter, against $261 million a year earlier. Management expects cash flow to turn positive in 2027.

Insmed Rose While Most Biotech Stocks Fell

Its sub-industry, biotechnology, counts 76 other companies worth $2 billion or more. Their median move that day was a fall of 0.6%. Of those companies, 50 fell and 26 rose, and none rose 5% or more. The health care sector ETF fell 2.0%, the same as the S&P 500.

Of the five companies we compare Insmed with, three fell, including United Therapeutics at 3.2%. Savara rose 10.4%. It is not one of the 76 biotech companies counted above.

Where Does Insmed Stock Stand Now?

A rise like this is rare for the stock. In the prior 365 days, only one other session brought a rise at least this large: a 33.9% gain on August 6, 2026.

The climb back has been quick. Insmed is up 53.6% over the past month, while the S&P 500 fell 7.4%. Over the past 12 months, though, the stock remains down 28.4%, against a 9.7% gain for the index.

Its $144.46 close sits well above the 12-month low close of $91.88 on June 10, 2026. It remains below the high close of $211.41 from December 1, 2025. At that price, Insmed trades at 20.8 times its sales over the past 12 months, against 3.1 for the S&P 500.

Insmed’s fourth-quarter 2026 report, the next one due, will show how BRINSUPRI’s sales for the year compare with the raised forecast.

Takeover talk can arrive at any time, and Insmed rose 20.6% on it in a single day. A portfolio spread across many stocks does not need anyone to see such news coming.

Stop Guessing. Start Positioning.

No one can predict surprises like this one. The Trefis High Quality (HQ) Portfolio doesn’t try: it holds 30 quality stocks in equal weight, so no single surprise decides your result. Come see how it works.

See How HQ Works

Spot an error or want more like this? Tell us in 10 seconds.